Filing Flows › Comparisons › TWST vs IPSC
Twist Bioscience vs Century Therapeutics: TWST and IPSC compared
Twist Bioscience is the larger company: $118M of revenue in its latest quarter (Q3 FY26) against $109M for Century Therapeutics (Q1 2025). Century Therapeutics is growing faster (128× against +23% a year earlier). Century Therapeutics is more profitable, with an operating margin of 67.9% against -30.6%.
Where the money goes: TWST and IPSC
Twist Bioscience (TWST) · Q3 FY26
Twist Bioscience, Q3 FY26: revenue $118M (+23% year over year), operating margin -30.6%, net loss $35.1M, operating cash flow $1.1M. The chart follows the revenue to costs, profit and cash.
Century Therapeutics (IPSC) · Q1 2025
Century Therapeutics, Q1 2025: revenue $109M (128× year over year), operating margin 67.9%, net earnings $76.6M, operating cash flow −$34.6M. The chart follows the revenue to costs, profit and cash.
| Twist Bioscience (TWST) | Century Therapeutics (IPSC) | |
|---|---|---|
| Latest quarter | Q3 FY26 | Q1 2025 |
| Revenue | $118M | $109M |
| Revenue growth, Y/Y | +23% | 128× |
| Operating margin | -30.6% | 67.9% |
| Net earnings | −$35.1M | $76.6M |
| Net margin | -29.6% | 70.1% |
| Operating cash flow | $1.1M | −$34.6M |
| Market value | $10.0B | — |
| Analysts’ mean target | $168.25 | — |
Where the revenue comes from
Twist Bioscience
- NGS applications: $61.8M (52%)
- DNA synthesis and protein solutions: $56.6M (48%)
Questions
Which is bigger, Twist Bioscience or Century Therapeutics?
Twist Bioscience is the larger company: $118M of revenue in its latest quarter (Q3 FY26) against $109M for Century Therapeutics (Q1 2025).
Is Twist Bioscience or Century Therapeutics growing faster?
Century Therapeutics is growing faster (128× against +23% a year earlier).
Which is more profitable, Twist Bioscience or Century Therapeutics?
Century Therapeutics is more profitable, with an operating margin of 67.9% against -30.6%.
More: Twist Bioscience earnings · how Twist Bioscience makes money · Century Therapeutics earnings · how Century Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 3, 2026; 10-Q filed May 15, 2025). Fiscal quarters can end on different dates. Not investment advice.